Beam Therapeutics Inc.
BEAMNasdaq
$27.53
↓ -3.0%Jul 17 close · end-of-day
Price
1Y↑ +37.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.8B
Enterprise Value
$1.7B
P/E
—
P/S
17.3
P/B
2.4
EV/EBITDA
—
PEG
—
FCF Yield
-13.5%
Dividend Yield
—
Revenue (TTM)
$164.0M
Net Income (TTM)
-$66.0M
Free Cash Flow (TTM)
-$383.8M
Gross Margin
—
Operating Margin
-226.6%
Net Margin
-40.2%
ROE
-5.7%
ROIC
-554.1%
Debt / Equity
0.1
Net Cash
$1.1B
Return 1Y
+34.6%
Company profile
Beam Therapeutics Inc. develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders.
- CEO
- John Evans
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 510
- Headquarters
- Massachusetts
- Website
- beamtx.com
Management & directors
- Evans John M.CEO
- Simon AmyChief Medical Officer
- Ciaramella GiuseppePresident
- Bellon ChristineChief Legal Officer
- Cavanagh Bethany JSVP, Finance and Treasurer
- Emany Sravan KumarChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
BEAM Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$31.7M↑ +324.9%
Diluted EPS-$0.91↓ -26.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $24,000.00 | $51.8M | $60.9M | $377.7M | $63.5M | $139.7M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$132.8M | -$392.5M | -$338.5M | -$176.5M | -$415.6M | -$383.7M |
| Net income | -$194.6M | -$370.7M | -$289.1M | -$132.5M | -$376.7M | -$80.0M |
| Diluted EPS | -$4.19 | -$5.77 | -$4.13 | -$1.72 | -$4.58 | -$0.81 |
| Operating cash flow | -$95.7M | -$66.3M | $22.5M | -$149.2M | -$347.2M | -$345.1M |
| Free cash flow | -$112.1M | -$113.1M | -$26.4M | -$182.9M | -$356.2M | -$360.0M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -553166.7% | -757.0% | -555.6% | -46.7% | -654.3% | -274.6% |
| Net margin | -810800.0% | -715.0% | -474.5% | -35.1% | -593.1% | -57.2% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11.8M | $14.3M | $30.1M | $7.5M | $8.5M | $9.7M | $114.1M | $31.7M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$104.9M | -$106.5M | -$100.0M | -$119.3M | -$120.2M | -$126.8M | -$17.4M | -$107.2M |
| Net income | -$91.1M | -$96.7M | -$90.4M | -$108.3M | -$102.3M | -$112.7M | $243.4M | -$94.3M |
| Diluted EPS | -$1.11 | -$1.17 | -$1.09 | -$1.23 | -$1.00 | -$1.10 | $2.52 | -$0.91 |
| Operating cash flow | -$83.0M | -$88.1M | -$76.4M | -$103.9M | -$76.5M | -$81.5M | -$83.3M | -$128.5M |
| Free cash flow | -$85.0M | -$89.7M | -$79.3M | -$106.9M | -$79.6M | -$86.5M | -$87.0M | -$130.7M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -891.1% | -746.4% | -332.7% | -1596.9% | -1419.2% | -1307.6% | -15.3% | -337.8% |
| Net margin | -773.5% | -677.5% | -300.5% | -1450.2% | -1208.3% | -1162.4% | 213.3% | -297.2% |
Company news
Jul 20, 2026
Jul 15, 2026
Jul 9, 2026
Jul 8, 2026
- 12d agoGene Editors, Including Powerhouse Beam Therapeutics, Diverge On Legal Battlefinance.yahoo.com
- 12d agoPRME Surges 15% After Winning Arbitration Against Beam — Clears Path To Human Trials For Its Gene-Editing Drugstocktwits.com
- 12d agoPrime Medicine Announces Positive Resolution to Arbitration with Beam Therapeuticsfinance.yahoo.com
- 12d agoA New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeuticsfool.com
- 12d agoPrime wins gene editing dispute; Saol claims latest post-Makary FDA reversalbiopharmadive.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-30 | Evans John M.· CEO | Sale | 23,100 | $34.26 | $791,482.23 | filing |
| 2026-06-30 | Evans John M.· CEO | Sale | 1,900 | $34.84 | $66,203.03 | filing |
| 2026-06-30 | Evans John M.· CEO | Option exercise | 25,000 | $1.03 | $25,750.00 | filing |
| 2026-06-30 | Simon Amy· Chief Medical Officer | Sale | 373 | $34.73 | $12,954.29 | filing |
| 2026-06-29 | Evans John M.· CEO | Sale | 13,421 | $35.13 | $471,528.05 | filing |
| 2026-06-29 | Evans John M.· CEO | Sale | 11,579 | $35.91 | $415,823.89 | filing |
| 2026-06-29 | Evans John M.· CEO | Option exercise | 18,663 | $0.67 | $12,504.21 | filing |
| 2026-06-29 | Evans John M.· CEO | Option exercise | 6,337 | $1.03 | $6,527.11 | filing |
| 2026-06-26 | FMR LLC | Sale | 251,488 | $35.26 | $8.9M | filing |
| 2026-06-25 | FMR LLC | Sale | 33,372 | $35.12 | $1.2M | filing |
| 2026-06-17 | Ciaramella Giuseppe· President | Option exercise | 29,000 | $1.03 | $29,870.00 | filing |
| 2026-06-17 | Ciaramella Giuseppe· President | Option exercise | 6,505 | $0.67 | $4,358.35 | filing |
| 2026-04-01 | Evans John M.· CEO | Sale | 30,078 | $24.58 | $739,317.24 | filing |
| 2026-04-01 | Ciaramella Giuseppe· President | Sale | 11,810 | $24.58 | $290,289.80 | filing |
| 2026-04-01 | Simon Amy· Chief Medical Officer | Sale | 6,700 | $24.58 | $164,686.00 | filing |
| 2026-04-01 | Bellon Christine· Chief Legal Officer | Sale | 5,956 | $24.58 | $146,398.48 | filing |
| 2026-04-01 | Cavanagh Bethany J· SVP, Finance and Treasurer | Sale | 3,242 | $24.58 | $79,688.36 | filing |
| 2026-03-31 | Evans John M.· CEO | Sale | 25,000 | $22.76 | $569,085.00 | filing |
| 2026-03-31 | Evans John M.· CEO | Option exercise | 25,000 | $0.67 | $16,750.00 | filing |
| 2026-03-31 | Emany Sravan Kumar· Chief Financial Officer | Award | 31,750 | $0.00 | $0.00 | filing |
| 2026-03-31 | Evans John M.· CEO | Award | 90,000 | $0.00 | $0.00 | filing |
| 2026-03-31 | Ciaramella Giuseppe· President | Award | 40,000 | $0.00 | $0.00 | filing |
| 2026-03-31 | Bellon Christine· Chief Legal Officer | Award | 20,000 | $0.00 | $0.00 | filing |
| 2026-03-31 | Cavanagh Bethany J· SVP, Finance and Treasurer | Award | 20,000 | $0.00 | $0.00 | filing |
| 2026-03-31 | Simon Amy· Chief Medical Officer | Award | 31,750 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.